Monte Rosa Therapeutics, Inc. GLUE
10.58 USD +0.01 (+0.09%)
At closeNov 9, 2026, 5:41 PM EST
10.58 0.00 0.00%
After hours · Nov 9, 5:41 PM ET
10.28 Day range 10.83
9.68 52-week range 25.77
- YTD
- -32.53%
- 1 year
- -14.05%
News
benzinga.com Monte Rosa Therapeutics Presents Preclinical Data Of MRT-8102 At ACR Convergence 2026 Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the presentation of preclinical…
benzinga.com Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $25 Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $27 to $25.
zacks.com Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.33 per share a year…- benzinga.com Monte Rosa Therapeutics Q3 EPS $0.03 Beats $(0.29) Estimate, Sales $54.366M Beat $29.750M Estimate Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.29) by 110.34 percent. This is a 109.09 percent increase over…
globenewswire.com Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose…
globenewswire.com Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today…
zacks.com Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? The consensus price target hints at a 152.9% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in…
globenewswire.com Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today…
benzinga.com Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In Psoriatic Arthritis Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has…
benzinga.com Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritisNovartis conducting study under global exclusive development and commercialization license agreement…
benzinga.com HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $25 price target.
benzinga.com Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease Monte Rosa Therapeutics reports positive Phase 1 trial data for MRT-8102 and outlines upcoming Phase 2 studies in inflammatory diseases.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…- benzinga.com Monte Rosa Reports Data From GFORCE-1, Phase 1 Study Evaluating MRT-8102, NEK7-Directed MGD Being Developed For Treatment Of Inflammatory Conditions Driven By NEK7/NLRP3 Pathway In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases,…
benzinga.com GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge? Monte Rosa Therapeutics shares surged 20.03% premarket as investors awaited clinical data from its experimental heart-risk drug.
benzinga.com HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25 HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy rating and announces Price Target of $25.
benzinga.com Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Vicor shares surged 12% after raising Q3 growth guidance above 30%; Roze AI led gainers, while Corteva plunged 57% premarket.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…- benzinga.com Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and maintains $27 price target.
benzinga.com Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $28 price target.
benzinga.com Monte Rosa Therapeutics Says First Patient Dosed In Modefire-1, Phase 2 Study Evaluating MRT-2359 In Combination With Apalutamide In Patients With mCRPC With AR Mutations Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safetyUpdated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide…
benzinga.com JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27 JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $27.- benzinga.com Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28 Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $35 to $28.
- benzinga.com Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27 Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $29 to $27.
- benzinga.com Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.38) by 13.16 percent. This is a 186.67 percent decrease over…
- benzinga.com Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27 Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and lowers the price target from $37 to $27.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…- benzinga.com Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35 Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $30 to $35.
- benzinga.com JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31 JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $30 to $31.
- benzinga.com Monte Rosa Therapeutics Q1 EPS $(0.45) Misses $(0.37) Estimate, Sales $4.210M Miss $10.883M Estimate Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.37) by 21.62 percent. This is a 178.95 percent decrease over…
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session 
benzinga.com Monte Rosa To Present Preclinical Data Highlighting Potential Of CCNE1-Directed MGD, MRT-55811, To Treat CCNE1-Amplified Solid Tumors At AACR Annual Meeting 2026 CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior…- benzinga.com Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $30 Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $34 to $30.
- benzinga.com Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $29 Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $30 to $29.
- benzinga.com Monte Rosa Therapeutics Q4 EPS $(0.55) Misses $(0.33) Estimate, Sales $2.781M Miss $15.506M Estimate Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.33) by 65.17 percent. This is a 339.13 percent decrease over…
- benzinga.com Monte Rosa Enters Into Supply Agreement With Johnson & Johnson To Evaluate MRT-2359 In Combination With ERLEADA For Treatment Of Patients With mCRPC With AR Mutations In Planned Phase 2 Study Expected To Initiate In Q3 Of 2026 MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in…
- benzinga.com Monte Rosa Highlights Updated Phase 1/2 Data Showing 67% Overall RECIST Disease Control And Tumor Reductions In Heavily Pretreated mCRPC In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate,…
- benzinga.com Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Raises Price Target to $37 Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $27.5 to $37.
- benzinga.com Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $30 Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $22 to $30.
- benzinga.com Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $34 Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $16 to $34.
- benzinga.com Monte Rosa Therapeutics Terminates ATM Prospectus After Selling 2.96M Shares For $24.2M In Net Proceeds Effective January 7, 2026, Monte Rosa Therapeutics, Inc. (the "Company") terminated the sales agreement prospectus (the "ATM Prospectus") filed with the Company's registration statement on Form S-3…
- benzinga.com Monte Rosa Therapeutics Commences Offering Of $200M Common Stock, Pre-Funded Warrants Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has…
benzinga.com Crude Oil Down 2%; ISM Services PMI Surges In December - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Monte Rosa's Experimental Drug Slashes Inflammation Linked To Heart Disease Monte Rosa revealed positive interim Phase 1 data of MRT-8102. Data showed safety, tolerability, and reduction in inflammatory markers.
benzinga.com Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - benzinga.com Market-Moving News for January 7th GLUE: 42% | Monte Rosa Therapeutics shares are trading higher after the company announced it will present interim clinical results from the ongoing Phase 1 study of NEK7-directed MGD MRT-8102. VTYX:…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Monte Rosa Therapeutics' Interim Data From an Ongoing Phase 1 Trial of MRT-8102 Shows C-Reactive Protein Level Reductions in Cardiovascular and Cardiometabolic Diseases In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases,…
- benzinga.com Monte Rosa Therapeutics To Present Interim Clinical Results From The Ongoing Phase 1 Study Of The NEK7-Directed MGD MRT-8102 On Wednesday, January 7, at 8:00 a.m. ET Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live…